VistaGen Therapeutics, Inc. (VTGN) |
|
0.2608 0.011 (4.53%)
|
02-07 16:00 |
|
Open: |
0.2595 |
Pre. Close: |
0.2495 |
|
High:
|
0.2675 |
Low:
|
0.21 |
|
Volume:
|
6,387,685 |
Market Cap:
|
54(M) |
|
|
|
Technical analysis |
as of: 2023-02-07 4:32:45 PM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 0.39 One year: 0.46 |
| Support: |
Support1: 0.19  Support2: 0.1 |
| Resistance: |
Resistance1: 0.34 Resistance2: 0.39 |
| Pivot: |
0.21 |
| Moving Average: |
MA(5): 0.26 MA(20): 0.2
MA(100): 0.14 MA(250): 0.6  |
| MACD: |
MACD(12,26): 0 Signal(9): 0 |
| Stochastic oscillator: |
%K(14,3): 66.3 %D(3): 74.9 |
| RSI: |
RSI(14): 65 |
| 52-week: |
High: 1.78 Low: 0.07 |
| Average Vol(K): |
3-Month: 6,870 (K) 10-Days: 7,176 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ VTGN ] has closed below upper band by 23.9%. Bollinger Bands are 160.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 5 days. This is a sign that the current trend might continue. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.27 - 0.27 |
0.27 - 0.27 |
|
Low:
|
0.21 - 0.21 |
0.21 - 0.21 |
|
Close:
|
0.26 - 0.26 |
0.26 - 0.26 |
|
Company Description |
|
VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in Phase III development for the acute treatment of anxiety in adults with social anxiety disorder. Its PH94B product candidature also has potential to treat a range of anxiety disorders, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder, preprocedural anxiety, and panic disorders. The company's CNS pipeline also comprises PH10, a rapid-onset neuroactive nasal spray, which is in preparation for Phase 2B clinical development as a stand-alone treatment for major depressive disorder (MDD); and AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is in development in combination with oral probenecid as a potential treatment of levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. It has contract research and development agreement with Cato Research Ltd.; license agreement with Pherin Pharmaceuticals, Inc.; and license and collaboration agreement with EverInsight Therapeutics Inc. VistaGen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California. |
Headline News |
Tue, 07 Feb 2023
VistaGen Therapeutics Inc : Losses of 5 cents announced for third quarter - Kalkine Media
Tue, 07 Feb 2023
VistaGen Therapeutics, Inc. (VTGN) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance
Tue, 07 Feb 2023
Vistagen Provides Corporate Update and Reports Fiscal 2023 Third ... - Valdosta Daily Times
Thu, 02 Feb 2023
NASDAQ Stocks Gaining Momentum Below $1: VVPR, FFIE, VTGN, IDEX - Faraday Future (NASDAQ:FFIE), Ideanomic - Benzinga
Fri, 27 Jan 2023
Should You Buy Vistagen Therapeutics Inc (VTGN) Stock After it Is Up 23.53% in a Week? - InvestorsObserver
Thu, 19 Jan 2023
Vistagen Poised To Begin Phase 1 Trial Of A Fast-Acting Antidepressant Nasal Spray In First Quarter Of 2023 - Marketscreener.com
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
200 (M) |
|
% Held by Insiders
|
1.4173e+008 (%) |
|
% Held by Institutions
|
0.8 (%) |
|
Shares Short
|
4,780 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-5.965e+007 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-5 |
|
Return on Assets (ttm)
|
616 |
|
Return on Equity (ttm)
|
-46 |
|
Qtrly Rev. Growth
|
1.06e+006 |
|
Gross Profit (p.s.)
|
-21.76 |
|
Sales Per Share
|
-151.71 |
|
EBITDA (p.s.)
|
1.94737e+006 |
|
Qtrly Earnings Growth
|
-0.3 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-55 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
-0.01 |
|
Price to Cash Flow
|
0.21 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
6.39e+006 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
